Weinshenker BG. (1994). „Natural history of multiple sclerosis.” (angol nyelven). Ann Neurol.36 (Suppl 1), S6-11. o. DOI:10.1002/ana.410360704. PMID 8017890.
Milo R, Kahana E (2010. március 1.). „Multiple sclerosis: geoepidemiology, genetics and the environment”. Autoimmun Rev9 (5), A387–94. o. DOI:10.1016/j.autrev.2009.11.010. PMID 19932200.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). „Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis” (angol nyelven). Neuroepidemiology27 (1), 28–32. o. DOI:10.1159/000094233. PMID 16804331.
Heesen C, Mohr DC, Huitinga I,et al. (2007. március). „Stress regulation in multiple sclerosis: current issues and concepts”. Mult. Scler.13 (2), 143–8. o. DOI:10.1177/1352458506070772. PMID 17439878.
Reyes S, Ramsay M, Ladhani S,et al. (2020). „Protecting people with multiple sclerosis through vaccination”. Pract Neurol20 (6), 435-445. o. DOI:10.1136/practneurol-2020-002527. PMID 32632038.
Alonso A, Hernán MA. (2008. July). „Temporal trends in the incidence of multiple sclerosis: a systematic review.” (angol nyelven). Neurology.71 (2), 129-35. o. DOI:10.1212/01.wnl.0000316802.35974.34. PMID 18606967.
Ascherio A, Munger KL, Simon KC (2010. június). „Vitamin D and multiple sclerosis” (angol nyelven). Lancet Neurol9 (6), 599–612. o. DOI:10.1016/S1474-4422(10)70086-7. PMID 20494325.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). „Vitamin D: an evidence-based review” (angol nyelven). J Am Board Fam Med22 (6), 698–706. o. DOI:10.3122/jabfm.2009.06.090037. PMID 19897699.
Dyment DA, Ebers GC, Sadovnick AD (2004. február). „Genetics of multiple sclerosis” (angol nyelven). Lancet Neurol3 (92), 104–10. o. DOI:10.1016/S1474-4422(03)00663-X. PMID 14747002.
Rosati G (2001. április). „The prevalence of multiple sclerosis in the world: an update” (angol nyelven). Neurol. Sci.22 (2), 117–39. o. DOI:10.1007/s100720170011. PMID 11603614.
Baranzini SE (2011. június). „Revealing the genetic basis of multiple sclerosis: are we there yet?”. Curr. Opin. Genet. Dev.21 (3), 317–24. o. DOI:10.1016/j.gde.2010.12.006. PMID 21247752.
Ceccarelli A, Bakshi R, Neema M. (2012. August). „MRI in multiple sclerosis: a review of the current literature.” (angol nyelven). Curr Opin Neurol.25 (4), 402-9. o. DOI:10.1097/WCO.0b013e328354f63f. PMID 22691759.
Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH. (1997. July). „Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.” (angol nyelven). Brain.120 (Pt 7), 1149-61. o. DOI:10.1093/brain/120.7.1149. PMID 9236628.
Link H, Huang YM. (2006. November). „Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.” (angol nyelven). J Neuroimmunol.180 (1-2), 17-28. o. DOI:10.1016/j.jneuroim.2006.07.006. PMID 16945427.
Luque FA, Jaffe SL. (2007). „Cerebrospinal fluid analysis in multiple sclerosis.” (angol nyelven). Int Rev Neurobiol.79, 341-56. o. DOI:10.1016/S0074-7742(07)79015-3. PMID 17531849.
Gronseth GS, Ashman EJ. (2000. May). „Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.” (angol nyelven). Neurology.54 (9), 1720-5. o. DOI:10.1212/WNL.54.9.1720. PMID 10802774.
Chirapapaisan N, Laotaweerungsawat S, Chuenkongkaew W, Samsen P, Ruangvaravate N, Thuangtong A, Chanvarapha N. (2015. February). „Diagnostic value of visual evoked potentials for clinical diagnosis of multiple sclerosis.” (angol nyelven). Doc Ophthalmol.130 (1), 25-30. o. DOI:10.1007/s10633-014-9466-6. PMID 25330954.
Lublin FD, Reingold SC, Cohen JA, et al. (2014. July). „Defining the clinical course of multiple sclerosis: the 2013 revisions.” (angol nyelven). Neurology.83 (3), 278-86. o. DOI:10.1212/WNL.0000000000000560. PMID 24871874.
Miller DH, Chard DT, Ciccarelli O. (2012. February). „Clinically isolated syndromes.” (angol nyelven). Lancet Neurol.11 (2), 157-69. o. DOI:10.1016/S1474-4422(11)70274-5. PMID 22265211.
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. (2006. April). „Secondary progressive multiple sclerosis: current knowledge and future challenges.” (angol nyelven). Lancet Neurol.5 (4), 343-54. o. DOI:10.1016/S1474-4422(06)70410-0. PMID 16545751.
Karussis D. (2014. February-March). „The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.” (angol nyelven). J Autoimmun.48-49, 134-42. o. DOI:10.1016/j.jaut.2014.01.022. PMID 24524923.
Drori T, Chapman J. (2014. April-May). „Diagnosis and classification of neuromyelitis optica (Devic's syndrome).” (angol nyelven). Autoimmun Rev.13 (4-5), 531-3. o. DOI:10.1016/j.autrev.2014.01.034. PMID 24424197.
Burton JM, O'Connor PW, Hohol M, Beyene J. (2012. December). „Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev.12, CD006921. o. DOI:10.1002/14651858.CD006921.pub3. PMID 23235634.
Tumani H. (2008. December). „Corticosteroids and plasma exchange in multiple sclerosis.” (angol nyelven). J Neurol.255 (Suppl 6), 36-42. o. DOI:10.1007/s00415-008-6007-9. PMID 19300958.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. (2011. January). „Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” (angol nyelven). Neurology.76 (3), 294-300. o. DOI:10.1212/WNL.0b013e318207b1f6. PMID 21242498.
Sorensen PS. (2014. June). „New management algorithms in multiple sclerosis.” (angol nyelven). Curr Opin Neurol.27 (3), 246-59. o. DOI:10.1097/WCO.0000000000000096. PMID 24759080.
McCormack PL. (2013. September). „Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.” (angol nyelven). Drugs.73 (13), 1463-81. o. DOI:10.1007/s40265-013-0102-7. PMID 23912625.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. (2013). „Mitoxantrone for multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev.5, CD002127. o. DOI:10.1002/14651858.CD002127.pub3. PMID 23728638.
Linker RA, Gold R. (2013. November). „Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.” (angol nyelven). Curr Neurol Neurosci Rep.13 (11), 394. o. DOI:10.1007/s11910-013-0394-8. PMID 24061646.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. (2012. November). „Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.” (angol nyelven). Lancet.380 (9856), 1829-39. o. DOI:10.1016/S0140-6736(12)61768-1. PMID 23122650.
Pryce, Gareth, et al. (2015). „Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids.” (angol nyelven). Journal of Neuroimmune Pharmacology10 (2), 281-292. o. DOI:10.1007/s11481-014-9575-8. PMID 25537576.
Olsen SA. (2009). „A review of complementary and alternative medicine (CAM) by people with multiple sclerosis.” (angol nyelven). Occup Ther Int.16 (1), 57-70. o. DOI:10.1002/oti.266. PMID 19222053.
Schwarz S, Knorr C, Geiger H, Flachenecker P. (2008. September). „Complementary and alternative medicine for multiple sclerosis.” (angol nyelven). Mult Scler.14 (8), 1113-9. o. DOI:10.1177/1352458508092808. PMID 18632773.
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. (2006. October). „Cannabis use in patients with multiple sclerosis.” (angol nyelven). Mult Scler.12 (5), 646-51. o. DOI:10.1177/1352458506070947. PMID 17086912.
Bennett M, Heard R. (2004). „Hyperbaric oxygen therapy for multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev. (1), CD003057. o. DOI:10.1002/14651858.CD003057.pub2. PMID 14974004.
Karpatkin HI, Napolione D, Siminovich-Blok B. (2014). „Acupuncture and multiple sclerosis: a review of the evidence.” (angol nyelven). Evid Based Complement Alternat Med.2014, 972935. o. DOI:10.1155/2014/972935. PMID 25045394.
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., et al. & UK MS research group. (2003). „Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.” (angol nyelven). Lancet362 (9395), 1517-1526. o. DOI:10.1016/S0140-6736(03)14738-1. PMID 14615106.
Makela P, Robson P, House H, Bateman C. (2004). „Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.” (angol nyelven). Multiple Sclerosis10 (4), 434-441. o. DOI:10.1191/1352458504ms1082oa. PMID 15327042.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. (2005). „Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.” (angol nyelven). J. Neurol. Neurosurg. Psychiatry76 (12), 1664--1669. o. DOI:10.1136/jnnp.2005.070136. PMID 16291891.
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., et al. & Rossi, P. (2011). „A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis.” (angol nyelven). European Journal of Neurology18 (9), 1122–1131. o. DOI:10.1111/j.1468-1331.2010.03328.x. PMID 21362108.
Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014. April). „Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders” (angol nyelven). Neurology82 (17), 1556-1563. o. DOI:10.1212/WNL.0000000000000363.. PMID 24778283.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). „Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.” (angol nyelven). Current medical research and opinion23 (1), 17-24. o. DOI:10.1185/030079906X158066. PMID 17257464.
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). „Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.” (angol nyelven). Neurology65 (6), 812-819. o. DOI:10.1212/01.wnl.0000176753.45410.8b. PMID 16186518.
Rog, David J., Turo J. Nurmikko, and Carolyn A. Young. (2007). „Oromucosal Δ 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.” (angol nyelven). Clinical therapeutics29 (9), 2068-2079. o. DOI:10.1016/j.clinthera.2007.09.013. PMID 18035205.
Serpell, Michael G., William Notcutt, and Christine Collin. (2013). „Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.” (angol nyelven). Journal of neurology260 (1), 285-295. o. DOI:10.1007/s00415-012-6634-z. PMID 22878432.
Haupts, M., Vila, C., Jonas, A., Witte, K., & Álvarez-Ossorio, L. (2016). „Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC: CBD Oromucosal Spray for Multiple Sclerosis Spasticity.” (angol nyelven). European Neurology75 (5-6), 236-243. o. DOI:10.1159/000445943. PMID 27160412.
Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). „An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.” (angol nyelven). Multiple Sclerosis10 (4), 425-433. o. DOI:10.1191/1352458504ms1063oa. PMID 15327041.
Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). „Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.” (angol nyelven). Multiple Sclerosis16 (11), 1349-1359. o. DOI:10.1177/1352458510378020. PMID 20829244.
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013). „Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A 2A receptors.” (angol nyelven). Neurobiology of disease (59), 141-150. o. DOI:10.1016/j.nbd.2013.06.016. PMID 23851307.
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., Calzado, M. A. (2012). „A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.” (angol nyelven). Journal of Neuroimmune Pharmacology7 (4), 1002-1016.. o. DOI:10.1007/s11481-012-9399-3. PMID 22971837.
Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, Amore M, Girardi P. (2012. December). „Suicide risk in multiple sclerosis: a systematic review of current literature.” (angol nyelven). J Psychosom Res.73 (6), 411-7. o. DOI:10.1016/j.jpsychores.2012.09.011. PMID 23148807.
Myhr KM, Riise T, Vedeler C, Nortvedt MW, Grønning R, Midgard R, Nyland HI. (2001. February). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.” (angol nyelven). Mult Scler.7 (1), 59-65. o. DOI:10.1177/135245850100700110. PMID 11321195.
elte.hu
anatomia.elte.hu
A mielinhuvely (magyar nyelven). anatomia.elte.hu. [2015. március 7-i dátummal az eredetiből archiválva]. (Hozzáférés: 2015. május 11.)
Clanet M (2008. június 1.). „Jean-Martin Charcot. 1825 to 1893” (PDF). Int MS J15 (2), 59–61. o. [2019. március 30-i dátummal az eredetiből archiválva]. PMID 18782501. (Hozzáférés: 2015. január 2.) * Charcot, J. (1868). „Histologie de la sclerose en plaques”. Gazette des hopitaux, Paris41, 554–5. o.
Nakahara, J, Maeda, M; Aiso, S; Suzuki, N (2012. február 1.). „Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.”. Clinical reviews in allergy & immunology42 (1), 26–34. o. PMID 22189514.
Weinshenker BG. (1994). „Natural history of multiple sclerosis.” (angol nyelven). Ann Neurol.36 (Suppl 1), S6-11. o. DOI:10.1002/ana.410360704. PMID 8017890.
Milo R, Kahana E (2010. március 1.). „Multiple sclerosis: geoepidemiology, genetics and the environment”. Autoimmun Rev9 (5), A387–94. o. DOI:10.1016/j.autrev.2009.11.010. PMID 19932200.
Clanet M (2008. június 1.). „Jean-Martin Charcot. 1825 to 1893” (PDF). Int MS J15 (2), 59–61. o. [2019. március 30-i dátummal az eredetiből archiválva]. PMID 18782501. (Hozzáférés: 2015. január 2.) * Charcot, J. (1868). „Histologie de la sclerose en plaques”. Gazette des hopitaux, Paris41, 554–5. o.
Amato MP, Ponziani G (1999. augusztus). „Quantification of impairment in MS: discussion of the scales in use” (angol nyelven). Mult. Scler.5 (4), 216–9. o. PMID 10467378.
Rudick RA, Cutter G, Reingold S (2002. október). „The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials” (angol nyelven). Mult. Scler.8 (5), 359–65. o. PMID 12356200.
Tsang BK, Macdonell R (2011. december 1.). „Multiple sclerosis- diagnosis, management and prognosis”. Australian family physician40 (12), 948–55. o. PMID 22146321.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). „Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis” (angol nyelven). Neuroepidemiology27 (1), 28–32. o. DOI:10.1159/000094233. PMID 16804331.
Heesen C, Mohr DC, Huitinga I,et al. (2007. március). „Stress regulation in multiple sclerosis: current issues and concepts”. Mult. Scler.13 (2), 143–8. o. DOI:10.1177/1352458506070772. PMID 17439878.
Reyes S, Ramsay M, Ladhani S,et al. (2020). „Protecting people with multiple sclerosis through vaccination”. Pract Neurol20 (6), 435-445. o. DOI:10.1136/practneurol-2020-002527. PMID 32632038.
Alonso A, Hernán MA. (2008. July). „Temporal trends in the incidence of multiple sclerosis: a systematic review.” (angol nyelven). Neurology.71 (2), 129-35. o. DOI:10.1212/01.wnl.0000316802.35974.34. PMID 18606967.
Pugliatti M, Sotgiu S, Rosati G (2002. July). „The worldwide prevalence of multiple sclerosis”. Clin Neurol Neurosurg104 (3), 182–91. o. PMID 12127652.
Ascherio A, Munger KL, Simon KC (2010. június). „Vitamin D and multiple sclerosis” (angol nyelven). Lancet Neurol9 (6), 599–612. o. DOI:10.1016/S1474-4422(10)70086-7. PMID 20494325.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). „Vitamin D: an evidence-based review” (angol nyelven). J Am Board Fam Med22 (6), 698–706. o. DOI:10.3122/jabfm.2009.06.090037. PMID 19897699.
Dyment DA, Ebers GC, Sadovnick AD (2004. február). „Genetics of multiple sclerosis” (angol nyelven). Lancet Neurol3 (92), 104–10. o. DOI:10.1016/S1474-4422(03)00663-X. PMID 14747002.
Hassan-Smith, G, Douglas, MR (2011. október 1.). „Epidemiology and diagnosis of multiple sclerosis.”. British journal of hospital medicine (London, England : 2005)72 (10), M146-51. o. PMID 22041658.
Rosati G (2001. április). „The prevalence of multiple sclerosis in the world: an update” (angol nyelven). Neurol. Sci.22 (2), 117–39. o. DOI:10.1007/s100720170011. PMID 11603614.
Baranzini SE (2011. június). „Revealing the genetic basis of multiple sclerosis: are we there yet?”. Curr. Opin. Genet. Dev.21 (3), 317–24. o. DOI:10.1016/j.gde.2010.12.006. PMID 21247752.
Ceccarelli A, Bakshi R, Neema M. (2012. August). „MRI in multiple sclerosis: a review of the current literature.” (angol nyelven). Curr Opin Neurol.25 (4), 402-9. o. DOI:10.1097/WCO.0b013e328354f63f. PMID 22691759.
Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH. (1997. July). „Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.” (angol nyelven). Brain.120 (Pt 7), 1149-61. o. DOI:10.1093/brain/120.7.1149. PMID 9236628.
Link H, Huang YM. (2006. November). „Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.” (angol nyelven). J Neuroimmunol.180 (1-2), 17-28. o. DOI:10.1016/j.jneuroim.2006.07.006. PMID 16945427.
Luque FA, Jaffe SL. (2007). „Cerebrospinal fluid analysis in multiple sclerosis.” (angol nyelven). Int Rev Neurobiol.79, 341-56. o. DOI:10.1016/S0074-7742(07)79015-3. PMID 17531849.
Gronseth GS, Ashman EJ. (2000. May). „Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.” (angol nyelven). Neurology.54 (9), 1720-5. o. DOI:10.1212/WNL.54.9.1720. PMID 10802774.
Chirapapaisan N, Laotaweerungsawat S, Chuenkongkaew W, Samsen P, Ruangvaravate N, Thuangtong A, Chanvarapha N. (2015. February). „Diagnostic value of visual evoked potentials for clinical diagnosis of multiple sclerosis.” (angol nyelven). Doc Ophthalmol.130 (1), 25-30. o. DOI:10.1007/s10633-014-9466-6. PMID 25330954.
Lublin FD, Reingold SC, Cohen JA, et al. (2014. July). „Defining the clinical course of multiple sclerosis: the 2013 revisions.” (angol nyelven). Neurology.83 (3), 278-86. o. DOI:10.1212/WNL.0000000000000560. PMID 24871874.
Miller DH, Chard DT, Ciccarelli O. (2012. February). „Clinically isolated syndromes.” (angol nyelven). Lancet Neurol.11 (2), 157-69. o. DOI:10.1016/S1474-4422(11)70274-5. PMID 22265211.
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. (2006. April). „Secondary progressive multiple sclerosis: current knowledge and future challenges.” (angol nyelven). Lancet Neurol.5 (4), 343-54. o. DOI:10.1016/S1474-4422(06)70410-0. PMID 16545751.
Stadelmann C, Brück W. (2004. November). „Lessons from the neuropathology of atypical forms of multiple sclerosis.” (angol nyelven). Neurol Sci.25 (Suppl 4), s319-22. o. PMID 15727225.
Karussis D. (2014. February-March). „The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.” (angol nyelven). J Autoimmun.48-49, 134-42. o. DOI:10.1016/j.jaut.2014.01.022. PMID 24524923.
Drori T, Chapman J. (2014. April-May). „Diagnosis and classification of neuromyelitis optica (Devic's syndrome).” (angol nyelven). Autoimmun Rev.13 (4-5), 531-3. o. DOI:10.1016/j.autrev.2014.01.034. PMID 24424197.
Burton JM, O'Connor PW, Hohol M, Beyene J. (2012. December). „Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev.12, CD006921. o. DOI:10.1002/14651858.CD006921.pub3. PMID 23235634.
Tumani H. (2008. December). „Corticosteroids and plasma exchange in multiple sclerosis.” (angol nyelven). J Neurol.255 (Suppl 6), 36-42. o. DOI:10.1007/s00415-008-6007-9. PMID 19300958.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. (2011. January). „Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” (angol nyelven). Neurology.76 (3), 294-300. o. DOI:10.1212/WNL.0b013e318207b1f6. PMID 21242498.
Hassan-Smith G, Douglas MR. (2011. November). „Management and prognosis of multiple sclerosis.” (angol nyelven). Br J Hosp Med (Lond).72 (11), M174-6. o. PMID 22082979.
Sorensen PS. (2014. June). „New management algorithms in multiple sclerosis.” (angol nyelven). Curr Opin Neurol.27 (3), 246-59. o. DOI:10.1097/WCO.0000000000000096. PMID 24759080.
McCormack PL. (2013. September). „Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.” (angol nyelven). Drugs.73 (13), 1463-81. o. DOI:10.1007/s40265-013-0102-7. PMID 23912625.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. (2013). „Mitoxantrone for multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev.5, CD002127. o. DOI:10.1002/14651858.CD002127.pub3. PMID 23728638.
Linker RA, Gold R. (2013. November). „Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.” (angol nyelven). Curr Neurol Neurosci Rep.13 (11), 394. o. DOI:10.1007/s11910-013-0394-8. PMID 24061646.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. (2012. November). „Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.” (angol nyelven). Lancet.380 (9856), 1829-39. o. DOI:10.1016/S0140-6736(12)61768-1. PMID 23122650.
Pryce, Gareth, et al. (2015). „Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids.” (angol nyelven). Journal of Neuroimmune Pharmacology10 (2), 281-292. o. DOI:10.1007/s11481-014-9575-8. PMID 25537576.
Huntley A. (2006. January). „A review of the evidence for efficacy of complementary and alternative medicines in MS.” (angol nyelven). Int MS J.13 (1), 5-12. o. PMID 16420779.
Olsen SA. (2009). „A review of complementary and alternative medicine (CAM) by people with multiple sclerosis.” (angol nyelven). Occup Ther Int.16 (1), 57-70. o. DOI:10.1002/oti.266. PMID 19222053.
Schwarz S, Knorr C, Geiger H, Flachenecker P. (2008. September). „Complementary and alternative medicine for multiple sclerosis.” (angol nyelven). Mult Scler.14 (8), 1113-9. o. DOI:10.1177/1352458508092808. PMID 18632773.
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. (2006. October). „Cannabis use in patients with multiple sclerosis.” (angol nyelven). Mult Scler.12 (5), 646-51. o. DOI:10.1177/1352458506070947. PMID 17086912.
Bennett M, Heard R. (2004). „Hyperbaric oxygen therapy for multiple sclerosis.” (angol nyelven). Cochrane Database Syst Rev. (1), CD003057. o. DOI:10.1002/14651858.CD003057.pub2. PMID 14974004.
Karpatkin HI, Napolione D, Siminovich-Blok B. (2014). „Acupuncture and multiple sclerosis: a review of the evidence.” (angol nyelven). Evid Based Complement Alternat Med.2014, 972935. o. DOI:10.1155/2014/972935. PMID 25045394.
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., et al. & UK MS research group. (2003). „Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.” (angol nyelven). Lancet362 (9395), 1517-1526. o. DOI:10.1016/S0140-6736(03)14738-1. PMID 14615106.
Makela P, Robson P, House H, Bateman C. (2004). „Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.” (angol nyelven). Multiple Sclerosis10 (4), 434-441. o. DOI:10.1191/1352458504ms1082oa. PMID 15327042.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. (2005). „Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.” (angol nyelven). J. Neurol. Neurosurg. Psychiatry76 (12), 1664--1669. o. DOI:10.1136/jnnp.2005.070136. PMID 16291891.
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., et al. & Rossi, P. (2011). „A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis.” (angol nyelven). European Journal of Neurology18 (9), 1122–1131. o. DOI:10.1111/j.1468-1331.2010.03328.x. PMID 21362108.
Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014. April). „Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders” (angol nyelven). Neurology82 (17), 1556-1563. o. DOI:10.1212/WNL.0000000000000363.. PMID 24778283.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). „Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.” (angol nyelven). Current medical research and opinion23 (1), 17-24. o. DOI:10.1185/030079906X158066. PMID 17257464.
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). „Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.” (angol nyelven). Neurology65 (6), 812-819. o. DOI:10.1212/01.wnl.0000176753.45410.8b. PMID 16186518.
Rog, David J., Turo J. Nurmikko, and Carolyn A. Young. (2007). „Oromucosal Δ 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.” (angol nyelven). Clinical therapeutics29 (9), 2068-2079. o. DOI:10.1016/j.clinthera.2007.09.013. PMID 18035205.
Serpell, Michael G., William Notcutt, and Christine Collin. (2013). „Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.” (angol nyelven). Journal of neurology260 (1), 285-295. o. DOI:10.1007/s00415-012-6634-z. PMID 22878432.
Haupts, M., Vila, C., Jonas, A., Witte, K., & Álvarez-Ossorio, L. (2016). „Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC: CBD Oromucosal Spray for Multiple Sclerosis Spasticity.” (angol nyelven). European Neurology75 (5-6), 236-243. o. DOI:10.1159/000445943. PMID 27160412.
Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). „An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.” (angol nyelven). Multiple Sclerosis10 (4), 425-433. o. DOI:10.1191/1352458504ms1063oa. PMID 15327041.
Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). „Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.” (angol nyelven). Multiple Sclerosis16 (11), 1349-1359. o. DOI:10.1177/1352458510378020. PMID 20829244.
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013). „Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A 2A receptors.” (angol nyelven). Neurobiology of disease (59), 141-150. o. DOI:10.1016/j.nbd.2013.06.016. PMID 23851307.
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., Calzado, M. A. (2012). „A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.” (angol nyelven). Journal of Neuroimmune Pharmacology7 (4), 1002-1016.. o. DOI:10.1007/s11481-012-9399-3. PMID 22971837.
Giacoppo, S., Rajan, T. S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2015). „Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.” (angol nyelven). European review for medical and pharmacological sciences19 (24), 4906-4919. o. PMID 26744883.
Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, Amore M, Girardi P. (2012. December). „Suicide risk in multiple sclerosis: a systematic review of current literature.” (angol nyelven). J Psychosom Res.73 (6), 411-7. o. DOI:10.1016/j.jpsychores.2012.09.011. PMID 23148807.
Myhr KM, Riise T, Vedeler C, Nortvedt MW, Grønning R, Midgard R, Nyland HI. (2001. February). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.” (angol nyelven). Mult Scler.7 (1), 59-65. o. DOI:10.1177/135245850100700110. PMID 11321195.
Clanet M (2008. június 1.). „Jean-Martin Charcot. 1825 to 1893” (PDF). Int MS J15 (2), 59–61. o. [2019. március 30-i dátummal az eredetiből archiválva]. PMID 18782501. (Hozzáférés: 2015. január 2.) * Charcot, J. (1868). „Histologie de la sclerose en plaques”. Gazette des hopitaux, Paris41, 554–5. o.
